

Amplia Therapeutics Limited (Company)

Securities Trading Policy

This securities trading policy sets out the Company's policy regarding trading in the Company's securities. This policy is separate from, and additional to, the legal constraints imposed by the *Corporations Act 2001 (Cth)* and the *ASX Listing Rules (Applicable Laws)*.

1. Scope of this Policy

- (a) This policy applies to all directors, executives, employees, contractors, consultants and advisors (together "**Designated Persons**") of the Company and its subsidiaries.
- (b) In this policy, "**Company Securities**" includes:
 - (i) any shares in the Company;
 - (ii) any other securities issued by the Company such as debentures and options; and
 - (iii) derivatives and other financial products issued by third parties in relation to the Company's shares, debentures and options.
- (c) In this policy to "**deal**" in Company Securities includes:
 - (i) subscribing for, purchasing or selling Company Securities or entering into an agreement to do any of those things, as principal or agent;
 - (ii) advising, procuring or encouraging another person (including a family member, friend, associate, colleague, family company or family trust) to subscribe for, purchase, sell Company Securities or enter into any agreement to do any of those things; and
 - (iii) entering into agreements or transactions which operate to limit the economic risk of a person's holdings in Company Securities.
- (d) In this policy "**Key Management Personnel**" means a director, executive or senior manager of the Company, or such other person who is "key management personnel" within the meaning of Accounting Standard AASB 124 and includes Relatives of Key Management Personnel.
- (e) In this policy "Relative" includes a spouse (or equivalent) or a dependant of the Key Management Personnel or employee or a company or other entity controlled by the Key Management Personnel or employee. For the avoidance of doubt, a Relative does not include a spouse (or equivalent) or dependant who is not controlled by the Key Management Personnel or employee but acts on their own initiative without reference to the Key Management Personnel or employee. In such cases, the Key Management

Personnel or employee should advise these persons that a risk exists that a Court could find a relevant association or that even without such an association, innuendo could arise if buying, selling or dealing occurs in the Company's Securities.

2. Purpose of the Policy

This policy sets out the circumstances in which the Designated Persons may deal in Company Securities with the objective that no Designated Person will contravene the requirements of the Applicable Laws.

- (a) The purpose of this policy is to:
 - (i) ensure that the Designated Persons adhere to high ethical and legal standards in relation to their personal investment in Company Securities;
 - (ii) ensure that the personal investments of the Designated Persons do not conflict with the interests of the Company and those of other holders of Company Securities;
 - (iii) preserve market confidence in the integrity of dealings in Company Securities; and
 - (iv) ensure the reputation of the Company is maintained.
- (b) This policy is not designed to prohibit the Designated Persons from investing in Company Securities but does recognise that there may be times when Designated Persons cannot, or should not, invest in Company Securities. This policy provides guidance to Designated Persons as to the times when Designated Persons may deal in Company Securities.

3. Outline of Corporations Act requirements

- (a) A person is in possession of "inside information" in relation to a company in circumstances where:
 - (i) the person possesses information that is not generally available and, if the information were generally available, a reasonable person would expect it to have a material effect on the price or value of any such company's securities; and
 - (ii) the person knows, or ought reasonably to know, that the information is not generally available and, if it were generally available, a reasonable person would expect it to have a material effect on the price or value any such company's securities.
- (b) A reasonable person would be taken to expect information to have a material effect on the price or value of company's securities if the information would, or would be likely to, influence persons who commonly invest in securities in deciding whether or not to deal in the relevant company's securities in any way. It does not matter how the Designated Person came to have the inside information.
- (c) If a Designated Person possesses "inside information" in relation to a company, the person must not:

- (i) deal in any securities of such company in any way; nor
 - (ii) directly or indirectly communicate the information, or cause the information to be communicated, to another person if the person knows, or ought reasonably to know, that the other person would, or would be likely to, deal in any securities of such company in any way or procure a third person to deal in any securities of such company in any way.
- (d) The Designated Persons may obtain inside information in relation to another company. For example, in the course of negotiating a transaction with the Company, another company might provide confidential information about itself.
- (e) A Designated Person who deals in Company Securities while in possession of "inside information" will be liable to both civil and criminal penalties.
- (f) Unpublished price sensitive "inside information" is information which the market is not aware and that a reasonable person would expect to have a material effect on the price or value of the Company's Securities, and includes:
- (i) a proposed major acquisition or disposition;
 - (ii) a significant business development or a proposed change in the nature of the Company's business;
 - (iii) details of material contracts that are being negotiated by the Company;
 - (iv) potential litigation that would have a substantial effect on the Company;
 - (v) a proposed change to the share capital structure of the Company; and
 - (vi) a major change to the Board or senior management.

4. Company's policy on dealing in Company Securities

- (a) **No short term trading:** The Company encourages Directors and employees to adopt a long-term attitude to their investment in the Company's securities.
- (b) Designated Persons must not deal in Company Securities at any time if they are in possession of any inside information relating to those securities.
- (c) **Requirement to obtain Chairman's and CEO's approval:** Notwithstanding anything in this policy, no Designated Person may deal in Company Securities at any time without the prior written approval of the Chairman (or his delegate) and the Chief Executive Officer of the Company (the Managing Director or such person performing the duties of a chief executive officer).

- (d) **Closed periods applicable to Key Management Personnel:** Key Management Personnel must refrain from dealing in Company Securities during the following periods (“**Closed Periods**”):
- fourteen (14) days prior to, and one (1) day after, the release of the Company’s Quarterly Reports (including the Appendix 4C);
 - fourteen (14) days prior to, and one (1) day after, the release of the Chairman's Address to the AGM
 - fourteen (14) days prior to, and one (1) day after, the release of any planned announcements relating to clinical results;
 - between 15 May and one (1) day after the release of the Company's Annual financial results;
 - between 15 November and one (1) day after the release of the Company's Half Yearly financial results;
 - and such other periods determined by the directors from time to time, unless exceptional circumstances apply under paragraph 4(e).
- (e) **Exceptional circumstances:** Subject always to paragraph 4(b), dealing in Company Securities by Key Management Personnel during a Closed Period may be permitted with the prior written approval of the Chairman, or in his absence, the Board or the Managing Director or Chief Executive Officer, if the following exceptional circumstances apply:
- (i) severe financial hardship;
 - (ii) in order to comply with an undertaking given to, or an order by, a court; or
 - (iii) such other exceptional circumstances as may from time to time be determined by the Chairman, or in his absence, the Board or the Managing Director or Chief Executive Officer.
- (f) **Employees other than Key Management Personnel:** Employees who are not Key Management Personnel may deal in Company Securities at any time provided the Employee is not in possession of any inside information relating to those securities.
- (g) **Exceptions to the policy:** Subject to the insider trading provisions of the Corporations Act, Designated Persons may at any time:
- (i) acquire ordinary shares in the Company by conversion of securities giving a right of conversion to ordinary shares;
 - (ii) acquire Company Securities under a bonus issue made to all holders of securities of the same class;
 - (iii) acquire Company Securities under a dividend reinvestment plan, a rights issue or a share purchase plan that is available to all holders of securities of the same class;

- (iv) acquire, or agree to acquire, options under a Company share option plan;
- (v) exercise options acquired under a Company share option plan (but may not sell all or part of the shares received upon exercise of the options other than in accordance with these procedures);
- (vi) transfer the Company Securities already held into a superannuation fund or other saving scheme in which the Designated Person is a beneficiary;
- (vii) invest in, or trade any unit of, a fund or other scheme where the assets of the fund or other scheme are invested at the discretion of a third party; and
- (viii) accept a takeover offer.

5. Consequences of breach

Strict compliance with this policy is mandatory for all persons covered under this policy. Breaches of this policy may damage the Company's reputation in the investment community and undermine confidence in the market for Company Securities. Accordingly, breaches will be taken very seriously by the Company and will be subject to disciplinary action, including possible termination of a person's employment or appointment.

6. Notification of Proposed Trade in Company Securities

6.1 Directors

- (a) Prior to trading in (either buying or selling) the Company's securities, Directors must notify the Chairman (or in the case of the Chairman he must notify the Managing Director or Chief Executive Officer) of their intention to trade and confirm that they are not in possession of any inside information.
- (b) In accordance with Listing Rules, a director must notify the ASX within 5 business days after any change in the Director's relevant interest in securities of the Company or a related body corporate of the Company.
- (c) A director must notify the Company Secretary in writing of the requisite information within 2 business days in order for the Company Secretary to make the necessary notifications to ASIC and ASX, as required by the ASX Listing Rules.

7. Employees

- (a) Prior to trading in (either buying or selling) the Company's securities, employees must notify the Managing Director, Chief Executive Officer or Company Secretary of their intention to trade and confirm that they are not in possession of any inside information.
- (b) Breaches of this policy will be subject to disciplinary action, which may include termination of employment.

- (c) The requirement to provide notice of an intention to trade in the Company's Securities does not apply to the acquisition of securities acquired through the exercise of options previously issued by the Company. However, the requirement does apply to the trading of the securities once they have been acquired.

8. Questions / further information

If you have any questions or need further information on how to comply with this policy, please contact the Company Secretary.

This Policy was approved by the Board on 1 May 2014.